Axon Enterprise (NASDAQ:AXON) Price Target Raised to $725.00

Axon Enterprise (NASDAQ:AXON) had its price target increased by research analysts at JMP Securities from $610.00 to $725.00 in a research note issued on Tuesday,Benzinga reports. The brokerage presently has a “market outperform” rating on the biotechnology company’s stock. JMP Securities’ price target indicates a potential upside of 10.33% from the stock’s previous close.

A number of other research analysts have also recently commented on the company. TD Cowen started coverage on Axon Enterprise in a research note on Wednesday, January 8th. They set a “buy” rating and a $700.00 target price on the stock. Morgan Stanley raised Axon Enterprise from an “equal weight” rating to an “overweight” rating and increased their price objective for the stock from $500.00 to $700.00 in a research note on Tuesday, December 3rd. Northland Securities upped their target price on Axon Enterprise from $365.00 to $550.00 and gave the stock an “outperform” rating in a report on Monday, November 11th. Robert W. Baird upped their target price on Axon Enterprise from $600.00 to $800.00 and gave the stock an “outperform” rating in a report on Friday, December 6th. Finally, Needham & Company LLC increased their price objective on Axon Enterprise from $525.00 to $600.00 and gave the company a “buy” rating in a report on Friday, November 8th. One analyst has rated the stock with a hold rating and fourteen have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $542.15.

Axon Enterprise Trading Down 0.2 %

AXON stock traded down $1.02 during midday trading on Tuesday, reaching $657.09. 257,316 shares of the company traded hands, compared to its average volume of 573,077. Axon Enterprise has a 52-week low of $252.20 and a 52-week high of $698.67. The company has a debt-to-equity ratio of 0.32, a quick ratio of 2.63 and a current ratio of 2.96. The business has a 50 day moving average of $620.41 and a 200-day moving average of $486.16. The firm has a market capitalization of $50.10 billion, a price-to-earnings ratio of 169.79, a P/E/G ratio of 6.54 and a beta of 1.05.

Insider Activity at Axon Enterprise

In related news, Director Julie A. Cullivan sold 1,261 shares of the business’s stock in a transaction on Wednesday, December 4th. The shares were sold at an average price of $682.06, for a total transaction of $860,077.66. Following the completion of the transaction, the director now owns 2,392 shares in the company, valued at approximately $1,631,487.52. The trade was a 34.52 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Caitlin Elizabeth Kalinowski sold 450 shares of the business’s stock in a transaction on Thursday, January 2nd. The stock was sold at an average price of $604.07, for a total transaction of $271,831.50. Following the transaction, the director now owns 6,929 shares of the company’s stock, valued at approximately $4,185,601.03. The trade was a 6.10 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 50,545 shares of company stock worth $30,721,337. Insiders own 5.70% of the company’s stock.

Institutional Investors Weigh In On Axon Enterprise

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. New Wave Wealth Advisors LLC purchased a new position in Axon Enterprise during the fourth quarter worth about $40,000. Y.D. More Investments Ltd acquired a new stake in shares of Axon Enterprise in the fourth quarter valued at approximately $45,000. Prestige Wealth Management Group LLC grew its position in shares of Axon Enterprise by 115.8% in the third quarter. Prestige Wealth Management Group LLC now owns 82 shares of the biotechnology company’s stock valued at $33,000 after purchasing an additional 44 shares during the last quarter. Stonebridge Financial Group LLC acquired a new stake in shares of Axon Enterprise in the fourth quarter valued at approximately $53,000. Finally, GPS Wealth Strategies Group LLC boosted its position in Axon Enterprise by 74.1% during the fourth quarter. GPS Wealth Strategies Group LLC now owns 94 shares of the biotechnology company’s stock worth $56,000 after acquiring an additional 40 shares during the last quarter. 79.08% of the stock is owned by hedge funds and other institutional investors.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.